Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M.

Bioorg Med Chem Lett. 2011 May 1;21(9):2725-31. doi: 10.1016/j.bmcl.2010.11.103. Epub 2010 Nov 26.

PMID:
21183342
2.

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Park WK, Kennedy RM, Larsen SD, Miller S, Roth BD, Song Y, Steinbaugh BA, Sun K, Tait BD, Kowala MC, Trivedi BK, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu GH, Robertson A, Sekerke C.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1151-6. Epub 2007 Dec 5.

PMID:
18155906
3.

Association of disorders in mineral metabolism with progression of chronic kidney disease.

Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP.

Clin J Am Soc Nephrol. 2006 Jul;1(4):825-31. Epub 2006 May 17.

4.

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.

Pfefferkorn JA, Song Y, Sun KL, Miller SR, Trivedi BK, Choi C, Sorenson RJ, Bratton LD, Unangst PC, Larsen SD, Poel TJ, Cheng XM, Lee C, Erasga N, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Olsen K, Mertz T, Sekerke C, Pavlovsky A, Harris MS, Bainbridge G, Caspers N, Chen H, Eberstadt M.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4538-44. Epub 2007 Jun 6.

PMID:
17574412
5.

Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.

Pfefferkorn JA, Choi C, Song Y, Trivedi BK, Larsen SD, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Sekerke C, Auerbach B, Pavlovsky A, Harris MS, Bainbridge G, Caspers N.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4531-7. Epub 2007 Jun 6.

PMID:
17574411
6.

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

Bratton LD, Auerbach B, Choi C, Dillon L, Hanselman JC, Larsen SD, Lu G, Olsen K, Pfefferkorn JA, Robertson A, Sekerke C, Trivedi BK, Unangst PC.

Bioorg Med Chem. 2007 Aug 15;15(16):5576-89. Epub 2007 May 17.

PMID:
17560788
7.

Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.

Filzen GF, Bratton L, Cheng XM, Erasga N, Geyer A, Lee C, Lu G, Pulaski J, Sorenson RJ, Unangst PC, Trivedi BK, Xu X.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3630-5. Epub 2007 Apr 24.

PMID:
17512197
8.

Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.

Bratton LD, Filzen GF, Geyer A, Hoffman JK, Lu G, Pulaski J, Trivedi BK, Unangst PC, Xu X.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3624-9. Epub 2007 Apr 24.

PMID:
17498950
9.
10.

Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease.

Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE.

Nephrol Dial Transplant. 2006 May;21(5):1257-62. Epub 2006 Jan 18.

PMID:
16421161
11.

Association of anemia with outcomes in men with moderate and severe chronic kidney disease.

Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE.

Kidney Int. 2006 Feb;69(3):560-4.

12.

Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor.

Li JJ, Carson KG, Trivedi BK, Yue WS, Ye Q, Glynn RA, Miller SR, Connor DT, Roth BD, Luly JR, Low JE, Heilig DJ, Yang W, Qin S, Hunt S.

Bioorg Med Chem. 2003 Aug 15;11(17):3777-90.

PMID:
12901923
13.

Medicinal chemistry in the development of societies. Biodiversity and natural products.

Monge A, Chorghade M, Erhardt PW, Ganellin CR, Koga N, Lindberg P, Perun TJ, Topliss JG, Trivedi BK, Wermuth CG.

Eur J Med Chem. 2000 Dec;35(12):1121-5.

PMID:
11248411
14.

15-Lipoxygenase and its inhibition: a novel therapeutic target for vascular disease.

Cornicelli JA, Trivedi BK.

Curr Pharm Des. 1999 Jan;5(1):11-20. Review.

PMID:
10066881
15.

CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile.

Trivedi BK, Hinton JP.

Pharm Biotechnol. 1998;11:481-505. Review. No abstract available.

PMID:
9760693
16.

Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.

Padia JK, Field M, Hinton J, Meecham K, Pablo J, Pinnock R, Roth BD, Singh L, Suman-Chauhan N, Trivedi BK, Webdale L.

J Med Chem. 1998 Mar 26;41(7):1042-9.

PMID:
9544204
17.

Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.

Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ, Hill D.

J Med Chem. 1998 Jan 1;41(1):38-45.

PMID:
9438020
18.

Inhibitors of acyl-CoA:cholesterol acyltransferase: novel trisubstituted ureas as hypocholesterolemic agents.

Purchase TS, Essenburg AD, Hamelehle KL, Hes MS, Holmes A, Krause BR, Stanfield RL, Trivedi BK.

Bioorg Med Chem. 1997 Apr;5(4):739-47.

PMID:
9158873
19.

Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties.

Sendobry SM, Cornicelli JA, Welch K, Bocan T, Tait B, Trivedi BK, Colbry N, Dyer RD, Feinmark SJ, Daugherty A.

Br J Pharmacol. 1997 Apr;120(7):1199-206.

20.
21.

Selective inhibition of tumor necrosis factor-induced vascular cell adhesion molecule-1 gene expression by a novel flavonoid. Lack of effect on transcription factor NF-kappa B.

W├Âlle J, Hill RR, Ferguson E, Devall LJ, Trivedi BK, Newton RS, Saxena U.

Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1501-8.

PMID:
8977455
22.

Nephrolithiasis: how it happens and what to do about it.

Trivedi BK.

Postgrad Med. 1996 Dec;100(6):63-7, 71-2, 77-8. Review.

PMID:
8960010
23.

Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.

Augelli-Szafran CE, Horwell DC, Kneen C, Ortwine DF, Pritchard MC, Purchase TS, Roth BD, Trivedi BK, Hill D, Suman-Chauhan N, Webdale L.

Bioorg Med Chem. 1996 Oct;4(10):1733-45.

PMID:
8931944
24.

Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.

Trivedi BK, Purchase TS, Holmes A, Augelli-Szafran CE, Essenburg AD, Hamelehle KL, Stanfield RL, Bousley RF, Krause BR.

J Med Chem. 1994 May 27;37(11):1652-9.

PMID:
8201599
25.

Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents.

Trivedi BK, Holmes A, Stoeber TL, Blankley CJ, Roark WH, Picard JA, Shaw MK, Essenburg AD, Stanfield RL, Krause BR.

J Med Chem. 1993 Oct 29;36(22):3300-7.

PMID:
8230120
26.

Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel beta-ketoamides as hypocholesterolemic agents.

Augelli-Szafran CE, Blankley CJ, Roth BD, Trivedi BK, Bousley RF, Essenburg AD, Hamelehle KL, Krause BR, Stanfield RL.

J Med Chem. 1993 Oct 1;36(20):2943-9.

PMID:
8411011
27.

Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bond.

Roark WH, Roth BD, Holmes A, Trivedi BK, Kieft KA, Essenburg AD, Krause BR, Stanfield RL.

J Med Chem. 1993 May 28;36(11):1662-8.

PMID:
8496932
28.

Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents.

Roth BD, Blankley CJ, Hoefle ML, Holmes A, Roark WH, Trivedi BK, Essenburg AD, Kieft KA, Krause BR, Stanfield RL.

J Med Chem. 1992 May 1;35(9):1609-17.

PMID:
1578488
29.

Application of polymerase chain reaction techniques to study of rabbit renin gene expression.

Trivedi BK, Briggs JP, Killen PD.

Kidney Int Suppl. 1991 Jun;32:S23-7.

PMID:
1881045
30.

Novel therapeutics acting via purine receptors.

Jacobson KA, Trivedi BK, Churchill PC, Williams M.

Biochem Pharmacol. 1991 May 15;41(10):1399-410. Review. No abstract available.

31.

N6-substituted adenosine receptor agonists: potential antihypertensive agents.

Trivedi BK, Blankley CJ, Bristol JA, Hamilton HW, Patt WC, Kramer WJ, Johnson SA, Bruns RF, Cohen DM, Ryan MJ.

J Med Chem. 1991 Mar;34(3):1043-9.

PMID:
2002448
32.

C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.

Trivedi BK, Bruns RF.

J Med Chem. 1989 Aug;32(8):1667-73.

PMID:
2754691
33.

N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor.

Trivedi BK, Bridges AJ, Patt WC, Priebe SR, Bruns RF.

J Med Chem. 1989 Jan;32(1):8-11. No abstract available.

PMID:
2909748
34.

N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.

Bridges AJ, Bruns RF, Ortwine DF, Priebe SR, Szotek DL, Trivedi BK.

J Med Chem. 1988 Jul;31(7):1282-5. No abstract available.

PMID:
3385722
35.
36.

N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.

Trivedi BK, Bristol JA, Bruns RF, Haleen SJ, Steffen RP.

J Med Chem. 1988 Jan;31(1):271-3.

PMID:
3336027
37.

N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.

Bridges AJ, Moos WH, Szotek DL, Trivedi BK, Bristol JA, Heffner TG, Bruns RF, Downs DA.

J Med Chem. 1987 Oct;30(10):1709-11. No abstract available.

PMID:
2888894
39.

Synthesis and antimetastatic properties of steroeoisomeric trycylic bis(dioxopiperazine) analogues in a B16 melanoma model.

Witiak DT, Trivedi BK, Campolito LB, Zwilling BS, Reiches NA.

J Med Chem. 1981 Nov;24(11):1329-32.

PMID:
7310809
40.

Vitamin B-12 model studies. Migration of the acrylate fragment in the carbon-skeleton rearrangement leading to alpha-methyleneglutaric acid.

Dowd P, Trivedi BK, Shairo M, Marwaha LK.

J Am Chem Soc. 1976 Nov 24;98(24):7875-7. No abstract available.

PMID:
993509
41.

Bacteriological water quality and incidence of water borne diseases in a rural population.

Trivedi BK, Gandhi HS, Shukla NK.

Indian J Med Sci. 1971 Nov;25(11):795-801. No abstract available.

PMID:
5138956
42.

A study of sickness absenteeism among textile workers of Kanpur.

Gandhi HS, Trivedi BK, Chakravarty AK.

Indian J Med Res. 1971 Sep;59(9):1467-79. No abstract available.

PMID:
5161575
43.

Family attitude and fertility pattern of a selected urban community.

Trivedi BK, Gandhi HS, Ali I.

Indian J Med Sci. 1971 Mar;25(3):158-65.

PMID:
5576739
44.

A study of height and weight of primary school children of a rural area near Kanpur.

Trivedi BK, Srivastava BC, Maheshwari BB.

Indian J Pediatr. 1971 Jan;38(276):20-6. No abstract available.

PMID:
5087643
45.

Awareness and acceptance of different family planning in a rural population.

Gandhi HS, Trivedi BK, Misra VN.

Indian J Public Health. 1969 Jul;13(3):130-43. No abstract available.

PMID:
5400697
46.

Radioactive vitamin B12 studies; experience with the urinary excretion test and the measurement of absorbed plasma radioactivity.

GOLDBERG SR, TRIVEDI BK, OLINER L.

J Lab Clin Med. 1957 Apr;49(4):583-9. No abstract available.

PMID:
13406394

Supplemental Content

Loading ...
Support Center